Drugs / GEN3017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06018129 | Sep 2023 → Feb 2025 | classic Hodgkin lymphoma, non-Hodgkin lymphoma | Genmab | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN3017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06018129 ↗ |
| Route | Subcutaneous | “GEN3017 will be administered via subcutaneous injections.” NCT06018129 ↗ |